Role of folylpolygutamate synthetase (FPGS) in antifolate chemotherapy; a biochemical and clinical update

Timothy W. Synold, Elizabeth M. Willits, Julio Barredo

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Even though folate antimetabolites were introduced over forty years ago, they continue to be the backbone of many active chemotherapeutic regimens used by medical and pediatric oncologists. The recognition of polyglutamylation by folylpolyglutamate synthetase (FPGS) as an important metabolic step in the "activation" of classical antifolates and novel drugs aimed at thymidylate synthase (TS) and de novo purine synthesis, has resulted in renewed interest in this class of drugs. In addition, the emergence of secondary neoplasms in patients treated with alkylating agents and topoisomerase inhibitors in contrast to the exceptional safety record of antimetabolites, underscores the need for clinical trials that incorporate new strategies with known active antimetabolites and novel promising agents. In that context, FPGS is an important target for further laboratory and clinical investigations.

Original languageEnglish
Pages (from-to)9-15
Number of pages7
JournalLeukemia and Lymphoma
Volume21
Issue number1-2
StatePublished - Dec 1 1996
Externally publishedYes

Fingerprint

Folic Acid Antagonists
Antimetabolites
Ligases
Drug Therapy
Topoisomerase Inhibitors
Thymidylate Synthase
Alkylating Agents
Folic Acid
Pharmaceutical Preparations
Clinical Trials
Pediatrics
Safety
Neoplasms

Keywords

  • Antifolates
  • Chemotherapy
  • FPGS
  • Polyglutamylation

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Role of folylpolygutamate synthetase (FPGS) in antifolate chemotherapy; a biochemical and clinical update. / Synold, Timothy W.; Willits, Elizabeth M.; Barredo, Julio.

In: Leukemia and Lymphoma, Vol. 21, No. 1-2, 01.12.1996, p. 9-15.

Research output: Contribution to journalArticle

@article{2a0a3c6b3ab8412192a13024831015bc,
title = "Role of folylpolygutamate synthetase (FPGS) in antifolate chemotherapy; a biochemical and clinical update",
abstract = "Even though folate antimetabolites were introduced over forty years ago, they continue to be the backbone of many active chemotherapeutic regimens used by medical and pediatric oncologists. The recognition of polyglutamylation by folylpolyglutamate synthetase (FPGS) as an important metabolic step in the {"}activation{"} of classical antifolates and novel drugs aimed at thymidylate synthase (TS) and de novo purine synthesis, has resulted in renewed interest in this class of drugs. In addition, the emergence of secondary neoplasms in patients treated with alkylating agents and topoisomerase inhibitors in contrast to the exceptional safety record of antimetabolites, underscores the need for clinical trials that incorporate new strategies with known active antimetabolites and novel promising agents. In that context, FPGS is an important target for further laboratory and clinical investigations.",
keywords = "Antifolates, Chemotherapy, FPGS, Polyglutamylation",
author = "Synold, {Timothy W.} and Willits, {Elizabeth M.} and Julio Barredo",
year = "1996",
month = "12",
day = "1",
language = "English",
volume = "21",
pages = "9--15",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "1-2",

}

TY - JOUR

T1 - Role of folylpolygutamate synthetase (FPGS) in antifolate chemotherapy; a biochemical and clinical update

AU - Synold, Timothy W.

AU - Willits, Elizabeth M.

AU - Barredo, Julio

PY - 1996/12/1

Y1 - 1996/12/1

N2 - Even though folate antimetabolites were introduced over forty years ago, they continue to be the backbone of many active chemotherapeutic regimens used by medical and pediatric oncologists. The recognition of polyglutamylation by folylpolyglutamate synthetase (FPGS) as an important metabolic step in the "activation" of classical antifolates and novel drugs aimed at thymidylate synthase (TS) and de novo purine synthesis, has resulted in renewed interest in this class of drugs. In addition, the emergence of secondary neoplasms in patients treated with alkylating agents and topoisomerase inhibitors in contrast to the exceptional safety record of antimetabolites, underscores the need for clinical trials that incorporate new strategies with known active antimetabolites and novel promising agents. In that context, FPGS is an important target for further laboratory and clinical investigations.

AB - Even though folate antimetabolites were introduced over forty years ago, they continue to be the backbone of many active chemotherapeutic regimens used by medical and pediatric oncologists. The recognition of polyglutamylation by folylpolyglutamate synthetase (FPGS) as an important metabolic step in the "activation" of classical antifolates and novel drugs aimed at thymidylate synthase (TS) and de novo purine synthesis, has resulted in renewed interest in this class of drugs. In addition, the emergence of secondary neoplasms in patients treated with alkylating agents and topoisomerase inhibitors in contrast to the exceptional safety record of antimetabolites, underscores the need for clinical trials that incorporate new strategies with known active antimetabolites and novel promising agents. In that context, FPGS is an important target for further laboratory and clinical investigations.

KW - Antifolates

KW - Chemotherapy

KW - FPGS

KW - Polyglutamylation

UR - http://www.scopus.com/inward/record.url?scp=0029658749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029658749&partnerID=8YFLogxK

M3 - Article

C2 - 8907263

AN - SCOPUS:0029658749

VL - 21

SP - 9

EP - 15

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1-2

ER -